Daraxonrasib FDA Approval Gives Pancreatic Cancer Its First RAS Pill

A long-awaited RAS drug reaches the clinic

On August 26, 2026, the U.S. Food and Drug Administration approved Rasonque (daraxonrasib). The agency described it as a first-in-class RAS inhibitor for the most common form of pancreatic cancer and said the decision came months ahead of schedule.11 The drug is made by Revolution Medicines. It is a pill taken once a day, and it is designed to block several forms of RAS, a protein that drives tumor growth.1 The label covers adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic therapy, as well as those who are not candidates for multiagent systemic therapy.4

Across trade press, patient advocates and academic cancer centers, the coverage calls this a landmark, and the reaction is easy to understand. Pancreatic adenocarcinoma makes up about 3.2% of cancer diagnoses but causes a much larger share of cancer deaths. The FDA attributes that gap to late detection, aggressive disease and a short list of treatment options.1 RAS has long been considered undruggable, and that view has shaped pancreatic cancer research for decades.3 The Guardian noted that the mutated protein this drug blocks drives more than 90% of pancreatic cancers, and that drugmakers spent decades failing to target it.

The trial behind the approval

The approval rests on RASolute 302, a phase 3 trial of 500 adults with metastatic pancreatic ductal adenocarcinoma. Each patient had received one earlier regimen containing a fluoropyrimidine or gemcitabine. Patients were randomly assigned to daraxonrasib 300 mg once daily or to one of four chemotherapy regimens chosen by the investigator.4 The trial ran at 59 sites in six countries.16

The main result is not in dispute. Median overall survival was 13.2 months with daraxonrasib and about 6.7 months with chemotherapy, and nearly every outlet describes this as a doubling.1152 The hazard ratio was 0.40, which is roughly a 60% lower risk of death. CURE and an oncologist writing for a general audience both highlighted that figure.310 In patients with RAS G12 mutations, median progression-free survival by blinded independent review was 7.3 months with the drug and 3.5 months with chemotherapy. Confirmed response rates were 33.2% and 11.8%.4

Some numbers differ slightly between outlets. Memorial Sloan Kettering and CURE give progression-free survival as 7.2 versus 3.6 months.143 CancerNetwork puts the chemotherapy-arm survival figure at 6.6 months for the G12-mutant subgroup and 6.7 months for the full population.4 These differences come from which population is being described, not from conflicting results. The size of the benefit is the same in every version.

The quality-of-life data may matter as much as survival for this disease. Patients on daraxonrasib took longer before their cancer-related pain worsened, at 9.2 months versus 3.8 months, and longer before their overall health status declined.4 MSK's Eileen O'Reilly, who led the trial at her center, put it simply: people live better for longer.14

A different side-effect profile, not a mild one

Coverage often calls the drug "chemotherapy-free," and the toxicity data partly support that. Grade 3 or higher treatment-related adverse events occurred in 43.6% of patients on daraxonrasib and 57.5% on chemotherapy. Only 1.2% stopped daraxonrasib because of side effects, compared with 11.2% who stopped chemotherapy.4 One New Orleans patient said taking the pill felt about like taking a Tylenol.2

That comparison can be misleading. In the trial, 85% of patients had rash, 58% had diarrhea and 53% had stomatitis (mouth sores).4 Oncology nursing coverage lists fatigue, abdominal pain, edema and hemorrhage among the most common reactions. It also stresses that because patients take the drug at home, nurses will need to track adherence and manage symptoms.5 The fair summary is that daraxonrasib replaces chemotherapy's toxicities with a different and generally more tolerable set, and that set still needs active management.

The label is broader than the trial

The biggest difference between the trial and the approval is who can get the drug. The trial required documented RAS mutation status. The FDA's approval does not require any particular RAS or KRAS mutation.1316 At the University of Miami's Sylvester cancer center, investigators said the approval was wider than they had expected.16 In an interview with CancerNetwork, an expert explained the reasoning. At least 90% of pancreatic cancers carry a RAS pathway alteration, and RAS signaling may still be active in many of the rest even when testing finds no mutation.15

The second part of the label is also worth noting. It covers patients who are not candidates for multiagent systemic therapy. WebMD points out that some of these patients could receive daraxonrasib without first trying another systemic treatment.13 The CancerNetwork interview treated this as a real but limited first-line opening, available when an oncologist judges a patient unfit for combination therapy.15 This expansion seems sensible to me, because the drug's mechanism does not depend on a single mutation. Still, it means the approval reaches beyond the population the drug was tested in, and real-world data on those patients will matter.

How fast the FDA moved, and how the speed is described

The regulatory story is almost as notable as the clinical one. The FDA said the approval came 6.5 months before the user-fee deadline.11 The application went through the Commissioner's National Priority Voucher pilot program. The drug also had Breakthrough Therapy designation, Orphan Drug designation and Priority Review.18 In a statement, acting FDA Commissioner Kyle Diamantas praised the agency's scientists for a review he called both fast and thorough.4

Outlets describe the timeline differently. ABC News reported that the voucher program cut review time from 12 months to 10.1 CancerNetwork reported that the application was accepted on July 22, 2026, with an expected review of one to two months, which fits an approval about five weeks later.4 Another CancerNetwork piece counted 135 days from the first public release of topline data on April 13 to the approval.15 The second account is the more plausible one. A ten-month review cannot be squared with a filing accepted in late July and approved in late August.

Access also came before approval. In May 2026 the FDA issued a "safe to proceed" letter that let Revolution Medicines open an expanded access program.17 The Guardian linked that step to a surge in public interest. Mass General Brigham says its oncologists began treating patients with the drug in July, before approval. Taken together, the expanded access program, the voucher review and the early approval show an agency willing to move very fast when a randomized phase 3 trial shows a clear survival benefit. The CancerNetwork interview raised the obvious question of whether this pace should become the norm and what clinicians and patients should watch for if it does.15 A drug with a clear benefit is a good test case for a fast review. A harder test will come with drugs whose data are less clear.

Who gets credit

Several institutions have claimed a share of the work, and the coverage reflects that. WBUR described the drug as developed by Dana-Farber, citing Brian Wolpin's lab.6 Other reports identify Revolution Medicines as the developer and the funder of the pivotal trial.14 MSK highlighted O'Reilly's role leading the trial, and the University of Cincinnati said it contributed lab research and trial sites.148 The most accurate reading is that a company built the molecule and paid for its development, while academic centers ran and published the science that proved it worked. The results were presented at ASCO 2026 and published at the same time in the New England Journal of Medicine.4

What comes next

The next questions are about earlier use and other countries. The phase 3 RASolute 303 trial is testing daraxonrasib as first-line treatment, alone and with gemcitabine plus nab-paclitaxel. RASolute 304 is testing it after surgery in patients whose tumors have been removed.4 In Europe, the EMA's drug committee started a phased review in July. In August, ESMO issued a guideline update recommending daraxonrasib monotherapy after chemotherapy fails in RAS G12–mutated disease.4 ESMO's narrower recommendation contrasts with the FDA's mutation-agnostic label, which suggests European regulators may be more cautious about who should receive the drug.

The drug does not cure the disease, and WebMD and MSK both say so plainly.1314 A median survival of just over a year is a real gain, but it still reflects how lethal metastatic pancreatic cancer is. The larger significance is that RAS can now be targeted with a drug, which the Sylvester team called a scientific milestone in its own right.16 If the first-line and post-surgery trials succeed, this approval will likely be remembered as the start of RAS-targeted treatment for the disease rather than its peak.